Risk assessment to guide cervical screening strategies in a large Chinese population

Fang Hui Zhao, Shang Ying Hu, Qian Zhang, Xun Zhang, Qin Jing Pan, Wen Hua Zhang, Julia C. Gage, Nicolas Wentzensen, Philip E. Castle, You Lin Qiao, Hormuzd A. Katki, Mark Schiffman

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Three different cervical screening methods [cytology, human papillomavirus(HPV) testing and visual inspection with acetic acid(VIA)] are being considered in China for the national cervical screening program. Comparing risks of CIN3 and cervical cancer (CIN3+) for different results can inform test choice and management guidelines. We evaluated the immediate risk of CIN3+ for different screening results generated from individual and combined tests. We compared tests using a novel statistic designed for this purpose called Mean Risk Stratification (MRS), in a pooled analysis of 17 cross sectional population-based studies of 30,371Chinese women screened with all 3 methods and diagnosed by colposcopically-directed biopsies. The 3 tests combined powerfully distinguished CIN3+ risk; triple-negative screening conferred a risk of 0.01%, while HPV-positive HSIL+ that was VIA-positive yielded a risk of 57.8%. Among the three screening tests, HPV status most strongly stratified CIN3+ risk. Among HPV-positive women, cytology was the more useful second test. In HPV-negative women, the immediate risks of CIN3+ ranged from 0.01% (negative cytology), 0.00% (ASC-US), 1.1% (LSIL), to 6.6 (HSIL+). In HPV-positive women, the CIN3+ risks were 0.9% (negative cytology), 3.6% (ASC-US), 6.3% (LSIL) and 38.5% (HSIL+). VIA results did not meaningful stratify CIN3+ risk among HPV-negative women with negative or ASC-US cytology; however, positive VIA substantially elevated CIN3+ risk for all other, more positive combinations of HPV and cytology compared with a negative VIA. Because all 3 screening tests had independent value in defining risk of CIN3+, different combinations can be optimized as pragmatic strategies in different resource settings.

Original languageEnglish (US)
Pages (from-to)2639-2647
Number of pages9
JournalInternational Journal of Cancer
Volume138
Issue number11
DOIs
StatePublished - Jun 1 2016

Fingerprint

Population
Cell Biology
Acetic Acid
Uterine Cervical Neoplasms
China
Cross-Sectional Studies
Guidelines
Biopsy
Atypical Squamous Cells of the Cervix

Keywords

  • cervical screening
  • cytology
  • HPV DNA testing
  • risk assessment
  • VIA

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Zhao, F. H., Hu, S. Y., Zhang, Q., Zhang, X., Pan, Q. J., Zhang, W. H., ... Schiffman, M. (2016). Risk assessment to guide cervical screening strategies in a large Chinese population. International Journal of Cancer, 138(11), 2639-2647. https://doi.org/10.1002/ijc.30012

Risk assessment to guide cervical screening strategies in a large Chinese population. / Zhao, Fang Hui; Hu, Shang Ying; Zhang, Qian; Zhang, Xun; Pan, Qin Jing; Zhang, Wen Hua; Gage, Julia C.; Wentzensen, Nicolas; Castle, Philip E.; Qiao, You Lin; Katki, Hormuzd A.; Schiffman, Mark.

In: International Journal of Cancer, Vol. 138, No. 11, 01.06.2016, p. 2639-2647.

Research output: Contribution to journalArticle

Zhao, FH, Hu, SY, Zhang, Q, Zhang, X, Pan, QJ, Zhang, WH, Gage, JC, Wentzensen, N, Castle, PE, Qiao, YL, Katki, HA & Schiffman, M 2016, 'Risk assessment to guide cervical screening strategies in a large Chinese population', International Journal of Cancer, vol. 138, no. 11, pp. 2639-2647. https://doi.org/10.1002/ijc.30012
Zhao, Fang Hui ; Hu, Shang Ying ; Zhang, Qian ; Zhang, Xun ; Pan, Qin Jing ; Zhang, Wen Hua ; Gage, Julia C. ; Wentzensen, Nicolas ; Castle, Philip E. ; Qiao, You Lin ; Katki, Hormuzd A. ; Schiffman, Mark. / Risk assessment to guide cervical screening strategies in a large Chinese population. In: International Journal of Cancer. 2016 ; Vol. 138, No. 11. pp. 2639-2647.
@article{76ff4da276114bb8a7011d4deb254308,
title = "Risk assessment to guide cervical screening strategies in a large Chinese population",
abstract = "Three different cervical screening methods [cytology, human papillomavirus(HPV) testing and visual inspection with acetic acid(VIA)] are being considered in China for the national cervical screening program. Comparing risks of CIN3 and cervical cancer (CIN3+) for different results can inform test choice and management guidelines. We evaluated the immediate risk of CIN3+ for different screening results generated from individual and combined tests. We compared tests using a novel statistic designed for this purpose called Mean Risk Stratification (MRS), in a pooled analysis of 17 cross sectional population-based studies of 30,371Chinese women screened with all 3 methods and diagnosed by colposcopically-directed biopsies. The 3 tests combined powerfully distinguished CIN3+ risk; triple-negative screening conferred a risk of 0.01{\%}, while HPV-positive HSIL+ that was VIA-positive yielded a risk of 57.8{\%}. Among the three screening tests, HPV status most strongly stratified CIN3+ risk. Among HPV-positive women, cytology was the more useful second test. In HPV-negative women, the immediate risks of CIN3+ ranged from 0.01{\%} (negative cytology), 0.00{\%} (ASC-US), 1.1{\%} (LSIL), to 6.6 (HSIL+). In HPV-positive women, the CIN3+ risks were 0.9{\%} (negative cytology), 3.6{\%} (ASC-US), 6.3{\%} (LSIL) and 38.5{\%} (HSIL+). VIA results did not meaningful stratify CIN3+ risk among HPV-negative women with negative or ASC-US cytology; however, positive VIA substantially elevated CIN3+ risk for all other, more positive combinations of HPV and cytology compared with a negative VIA. Because all 3 screening tests had independent value in defining risk of CIN3+, different combinations can be optimized as pragmatic strategies in different resource settings.",
keywords = "cervical screening, cytology, HPV DNA testing, risk assessment, VIA",
author = "Zhao, {Fang Hui} and Hu, {Shang Ying} and Qian Zhang and Xun Zhang and Pan, {Qin Jing} and Zhang, {Wen Hua} and Gage, {Julia C.} and Nicolas Wentzensen and Castle, {Philip E.} and Qiao, {You Lin} and Katki, {Hormuzd A.} and Mark Schiffman",
year = "2016",
month = "6",
day = "1",
doi = "10.1002/ijc.30012",
language = "English (US)",
volume = "138",
pages = "2639--2647",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Risk assessment to guide cervical screening strategies in a large Chinese population

AU - Zhao, Fang Hui

AU - Hu, Shang Ying

AU - Zhang, Qian

AU - Zhang, Xun

AU - Pan, Qin Jing

AU - Zhang, Wen Hua

AU - Gage, Julia C.

AU - Wentzensen, Nicolas

AU - Castle, Philip E.

AU - Qiao, You Lin

AU - Katki, Hormuzd A.

AU - Schiffman, Mark

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Three different cervical screening methods [cytology, human papillomavirus(HPV) testing and visual inspection with acetic acid(VIA)] are being considered in China for the national cervical screening program. Comparing risks of CIN3 and cervical cancer (CIN3+) for different results can inform test choice and management guidelines. We evaluated the immediate risk of CIN3+ for different screening results generated from individual and combined tests. We compared tests using a novel statistic designed for this purpose called Mean Risk Stratification (MRS), in a pooled analysis of 17 cross sectional population-based studies of 30,371Chinese women screened with all 3 methods and diagnosed by colposcopically-directed biopsies. The 3 tests combined powerfully distinguished CIN3+ risk; triple-negative screening conferred a risk of 0.01%, while HPV-positive HSIL+ that was VIA-positive yielded a risk of 57.8%. Among the three screening tests, HPV status most strongly stratified CIN3+ risk. Among HPV-positive women, cytology was the more useful second test. In HPV-negative women, the immediate risks of CIN3+ ranged from 0.01% (negative cytology), 0.00% (ASC-US), 1.1% (LSIL), to 6.6 (HSIL+). In HPV-positive women, the CIN3+ risks were 0.9% (negative cytology), 3.6% (ASC-US), 6.3% (LSIL) and 38.5% (HSIL+). VIA results did not meaningful stratify CIN3+ risk among HPV-negative women with negative or ASC-US cytology; however, positive VIA substantially elevated CIN3+ risk for all other, more positive combinations of HPV and cytology compared with a negative VIA. Because all 3 screening tests had independent value in defining risk of CIN3+, different combinations can be optimized as pragmatic strategies in different resource settings.

AB - Three different cervical screening methods [cytology, human papillomavirus(HPV) testing and visual inspection with acetic acid(VIA)] are being considered in China for the national cervical screening program. Comparing risks of CIN3 and cervical cancer (CIN3+) for different results can inform test choice and management guidelines. We evaluated the immediate risk of CIN3+ for different screening results generated from individual and combined tests. We compared tests using a novel statistic designed for this purpose called Mean Risk Stratification (MRS), in a pooled analysis of 17 cross sectional population-based studies of 30,371Chinese women screened with all 3 methods and diagnosed by colposcopically-directed biopsies. The 3 tests combined powerfully distinguished CIN3+ risk; triple-negative screening conferred a risk of 0.01%, while HPV-positive HSIL+ that was VIA-positive yielded a risk of 57.8%. Among the three screening tests, HPV status most strongly stratified CIN3+ risk. Among HPV-positive women, cytology was the more useful second test. In HPV-negative women, the immediate risks of CIN3+ ranged from 0.01% (negative cytology), 0.00% (ASC-US), 1.1% (LSIL), to 6.6 (HSIL+). In HPV-positive women, the CIN3+ risks were 0.9% (negative cytology), 3.6% (ASC-US), 6.3% (LSIL) and 38.5% (HSIL+). VIA results did not meaningful stratify CIN3+ risk among HPV-negative women with negative or ASC-US cytology; however, positive VIA substantially elevated CIN3+ risk for all other, more positive combinations of HPV and cytology compared with a negative VIA. Because all 3 screening tests had independent value in defining risk of CIN3+, different combinations can be optimized as pragmatic strategies in different resource settings.

KW - cervical screening

KW - cytology

KW - HPV DNA testing

KW - risk assessment

KW - VIA

UR - http://www.scopus.com/inward/record.url?scp=84957639365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957639365&partnerID=8YFLogxK

U2 - 10.1002/ijc.30012

DO - 10.1002/ijc.30012

M3 - Article

C2 - 26800481

AN - SCOPUS:84957639365

VL - 138

SP - 2639

EP - 2647

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 11

ER -